Peptide therapy hype on TikTok: what the science actually supports

What's this video probably claiming?

Accounts in the peptide therapy niche on TikTok tend to follow a predictable script. Based on the category tags, @peptidepulse3 is likely discussing one or more of the following: that BPC-157 repairs tendons and gut lining faster than conventional treatment, that a CJC-1295 and ipamorelin combination meaningfully raises growth hormone levels, that MK-677 is a safe, oral alternative to injectable growth hormone, or that GHK-Cu reverses visible skin aging. The framing in these videos almost always presents animal data or anecdotal reports as if they were established human clinical outcomes. Peptide content creators frequently conflate rodent pharmacology with human physiology, skip over regulatory status, and rarely mention that most of these compounds have not completed Phase 2 or Phase 3 human trials. That gap between what rodent models show and what a human body actually does is not a minor footnote. It is the entire story.

What does the science actually show?

Let's go compound by compound because lumping all peptides together is exactly the kind of lazy thinking these videos rely on.

• BPC-157: Animal studies, including work by Sikiric et al. (2018, Current Pharmaceutical Design), show accelerated tendon and gut mucosal healing in rats at roughly 10 mcg/kg. No completed randomized controlled trial in humans exists as of 2024.
• CJC-1295 and ipamorelin: Ionescu and Frohman (2004, Journal of Clinical Endocrinology and Metabolism) documented growth hormone pulse amplification with GHRH analogs, but the clinical population was adults with verified GH deficiency, not healthy people seeking body composition changes.
• MK-677: Nass et al. (2008, Annals of Internal Medicine) found MK-677 increased IGF-1 by roughly 40% over 12 months in older adults but also increased fasting glucose and insulin resistance. That tradeoff is almost never mentioned on TikTok.
• GHK-Cu: Pickart and Margolina (2018, Frontiers in Aging Neuroscience) reviewed in vitro and small human cosmetic trials showing collagen synthesis signals, but the leap from petri dish to meaningful clinical anti-aging is not supported by large trials.

Where does the social media noise diverge from clinical reality?

The divergence is not subtle. Social media peptide content routinely presents three problems that individually would get a pharmaceutical ad rejected by regulators. First, efficacy claims are built on animal or in vitro data presented without that qualifier. Second, safety is treated as an afterthought or not discussed at all. Semax and selank, for instance, are registered drugs in Russia with some human neurological trial data, but that data is limited, often published in journals with poor international peer review standards, and the compounds are not FDA-approved. Third, the dose-response relationship is essentially ignored. MK-677 at doses circulating in wellness communities (commonly 25 mg/day) was associated in the Nass trial with edema in 73% of participants and meaningful insulin sensitivity changes. A creator telling you to "try MK-677 for better sleep and muscle" without that context is not giving you information. They are giving you marketing.

What should you actually know?

Peptides are not inherently a scam category, but the TikTok framing around them almost always is. Here is what evidence-based medicine actually supports at this stage. BPC-157 has real mechanistic plausibility from animal data and warrants further human investigation, but it is not a proven therapeutic in humans. Growth hormone secretagogues like ipamorelin and CJC-1295 have legitimate clinical interest in GH-deficient populations, not in healthy adults chasing body composition goals. MK-677's oral bioavailability is real, but so are its metabolic risks, which are dose-dependent and under-discussed. GHK-Cu in topical formulations has cosmetic trial support, but injectable GHK-Cu claims go well beyond what the data shows. Semax and selank have very thin English-language clinical evidence. Any peptide protocol should involve a licensed clinician who reviews your bloodwork, not a 60-second video from someone whose credentials are a username. Regulatory status matters too: most of these compounds are research chemicals or compounded preparations, not FDA-approved drugs, and that distinction affects quality control, dosing accuracy, and liability.